Tikva Allocell announces Joint Laboratory with A*STAR’s Institute of Molecular and Cell Biology

Tikva announces setting up of joint laboratory with A*STAR’s Institute of Molecular and Cell Biology (IMCB) to progress its pipeline of promising cell therapies against solid tumors.

SINGAPORE – 15 Feb 2024 – Tikva Allocell Pte Ltd (“Tikva” or the “Company”), a late preclinical ‘off-the-shelf’ cell therapy company targeting solid tumors announces setting up of joint laboratory with A*STAR’s Institute of Molecular and Cell Biology (IMCB) to progress its pipeline of promising cell therapies against solid tumors.

Tikva’s allogeneic cell therapy platform utilizes novel protein and cell engineering strategies to overcome key off-the-shelf therapy challenges such as cell persistence and durability. The company is founded by Dr. Ivan Horak – a cancer therapy veteran with extensive experience in the global pharmaceutical industry, and co-founded by Dr. Malcom Brenner, Dr. Cliona Rooney and Dr. Helen Heslop, experts in cell therapy and who will serve as scientific advisors of the company. Tikva is targeting difficult-to-treat solid tumors e.g. non-small cell lung, colorectal, gastric and triple negative breast cancers with its pipeline that is expected to enter clinical trial soon.

The Tikva-IMCB joint laboratory combines Tikva’s capabilities in the design, engineering and process development of chimeric antigen receptor T cell (CAR-T) products, with IMCB’s expertise in generating preclinical models for in vivo safety and efficacy testing of the cell therapies. This synergistic collaboration will accelerate the development of Tikva’s innovative pipeline of allogeneic CAR-Ts for the treatment of solid tumors.

Founder and Chief Executive Officer Dr. Ivan Horak stated, “Tikva Allocell is pursuing an ambitious vision of targeting solid tumors with its innovative first-in-class second generation ‘off-the-shelf’ cell therapy platform. We are backed by the right science and propelled by a highly experienced team of researchers and collaborators with proven track record of cell therapy execution. We look forward to executing on our clinical milestones this year and bringing these life-saving therapies to patients in need.”

Dr. Chen Qingfeng, Co-Principal Investigator for the joint laboratory and Senior Principal Scientist at IMCB, shared that “The rise of allogenic cell therapies, exemplified by advancements at Tikva, underscores a growing demand for resilient preclinical models capable of swiftly screening and validating these innovative approaches. IMCB’s expertise in disease modeling can help to facilitate validation and accelerate the overall drug development process. Through the collaboration, we hope to translate lab discoveries into life-saving medicines and solutions, in alignment with Singapore’s goal to be a regional hub for cell and gene therapies.”

About Tikva Allocell

Tikva Allocell Pte Ltd is a late preclinical stage biotech company headquartered in Singapore. Our cell therapy platform is an off-the-shelf CAR-T therapy, utilizing second-generation allogeneic T cells prepared from the blood of Epstein-Barr virus (EBV)-positive healthy individuals. Our approach exploits the intrinsic properties of Virus-Specific T cells (VSTs), enhanced by IP-protected novel repurposing strategies to enhance cell performance and safely target patients with solid tumors including gastric, prostate and triple negative breast cancers.

For more information on Tikva, please visit www.tikvaallocell.com.

Investors and Media Contact

Wilson W. Cheung

Chief Financial Officer
Share the Post:

Related Posts